Phase 12 Study of Iberdomide with Daratumumab, Elotuzumab, and Dexamethasone for Relapsed Multiple Myeloma

What this Trial Is About

Researchers are studying a combination treatment involving iberdomide, daratumumab, elotuzumab, and dexamethasone for patients with relapsed multiple myeloma, a type of blood cancer that has returned after previous improvement. This phase III trial aims to find the safest dose and evaluate how well this combination works to control the disease and improve patient outcomes. The study also looks at effects on the immune system and the ability of cancer cells to grow and spread. Participants receive iberdomide orally once daily for 21 days each 28-day cycle. Daratumumab is given under the skin on specific days during the treatment cycles, while elotuzumab is given intravenously on scheduled days. Dexamethasone is taken orally on certain days for up to 12 cycles or as decided by the doctor. Treatment can continue for up to 36 cycles unless the disease worsens or side effects become unacceptable. Bone marrow tests and imaging scans are performed during screening, treatment, and at the end of treatment. Throughout the study, participants undergo evaluations including bone marrow aspiration and biopsy, CT scans, MRIs, PETCT scans, and possibly chest x-rays. After finishing treatment, patients are followed up at 7 days, 30 days, and then every 3 to 6 months for up to three years to monitor response and side effects. The study measures include the best dose tolerated, response rates, survival times, time to disease response, and any treatment-related side effects.

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma